Abstract:Despite extensive research, the exact mechanisms involved in colorectal cancer (CRC) etiology and pathogenesis remain unclear. This study aimed to examine the correlation between tumor-associated alternative splicing (AS) events and tumor immune infiltration (TII) in CRC. We analyzed transcriptome profiling and clinical CRC data from The Cancer Genome Atlas (TCGA) database and lists of AS-related and immune-related signatures from the SpliceSeq and Innate databases, respectively to develop and validate a risk model of differential AS events and subsequently a TII risk model. We then conducted a two-factor survival analysis to study the association between TII and AS risk and evaluated the associations between immune signatures and six types of immune cells based on the TIMER database. Subsequently, we studied the distribution of six types of TII cells in high- and low-risk groups for seven AS events and in total. We obtained the profiles of AS events/genes for 484 patients, which included 473 CRC tumor samples and 41 corresponding normal samples, and detected 22581 AS events in 8122 genes. Exon Skip (ES) (8446) and Mutually Exclusive Exons (ME) (74) exhibited the most and fewest AS events, respectively. We then classified the 433 patients with CRC into low-risk (n = 217) and high-risk (n = 216) groups based on the median risk score in different AS events. Compared with patients with low-risk scores (mortality = 11.8%), patients with high-risk scores were associated with poor overall survival (mortality = 27.6%). The risk score, cancer stage, and pathological stage (T, M, and N) were closely correlated with prognosis in patients with CRC ( P < 0.001). We identified 6479 differentially expressed genes from the transcriptome profiles of CRC and intersected 468 differential immune-related signatures. High-AS-risk and high-TII-risk predicted a poor prognosis in CRC. Different AS types were associated with different TII risk characteristics. Alternate Acceptor site (AA) and Alternate Promoter (AP) events directly affected the concentration of CD4T cells, and the level of CD8T cells was closely correlated with Alternate Terminator (AT) and Exon Skip (ES) events. Thus, the concentration of CD4T and CD8T cells in the CRC immune microenvironment was not specifically modulated by AS. However, B cell, dendritic cell, macrophage, and neutrophilic cell levels were strongly correlated with AS events. These results indicate adverse associations between AS event risk levels and immune cell infiltration density. Taken together, our findings show a clear association between tumor-associated alternative splicing and immune cell infiltration events and patient outcome and could form a basis for the identification of novel markers and therapeutic targets for CRC and other cancers in the future.

Identification of Novel Alternative Splicing Isoform Biomarkers and Their Association with Overall Survival in Colorectal Cancer

Systematic profiling of alternative splicing of ZNF family in Colorectal cancer

Novel prognostic alternative splicing events in colorectal Cancer: Impact on immune infiltration and therapy response

Analysis of Colorectal Cancer-Associated Alternative Splicing Based on Transcriptome.

Identification of Key Prognostic Alternative Splicing Events of Costimulatory Molecule-Related Genes in Colon Cancer

Systematic Profiling of Alternative Splicing Events and Splicing Factors in Left- and Right-Sided Colon Cancer

Alternative spliced variants as biomarkers of colorectal cancer.

Deciphering Alternative Splicing Events and Their Therapeutic Implications in Colorectal Cancer

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer

Screening Gene Expression-Related Alternative Splicing Event Signature for Colon Cancer Prognostic Prediction

Pan-cancer Analysis of Clinical Relevance of Alternative Splicing Events in 31 Human Cancers

Systematic Profiling of Alternative Splicing for Sarcoma Patients Reveals Novel Prognostic Biomarkers Associated with Tumor Microenvironment and Immune Cells.

Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma.

Prognostic Alternative Mrna Splicing Signature in Hepatocellular Carcinoma: a Study Based on Large-Scale Sequencing Data

An integrative framework identifies alternative splicing events in colorectal cancer development

Features of Alternative Splicing in Stomach Adenocarcinoma and Their Clinical Implication: a Research Based on Massive Sequencing Data

Identification of differentially expressed genes and splicing events in early-onset colorectal cancer

Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma

Identification of Alternatively Spliced Mrna Variants Related to Cancers by Genome-Wide ESTs Alignment

Alternative splicing of mRNA in colorectal cancer: new strategies for tumor diagnosis and treatment